Remove Clinical Development Remove Clinical Trials Remove Regulation Remove Trials
article thumbnail

Interview: Is global AI regulation really revolutionizing pharma and clinical trials?

Outsourcing Pharma

OSP spoke to Berkeley Research Group healthcare managing director, Wendy Cheng for a discussion around developments in AI regulation for pharmaceuticals, clinical trials, and drug development at a global scale.

article thumbnail

Interview: Is global AI regulation really revolutionizing pharma and clinical trials?

Outsourcing Pharma

OSP spoke to Berkeley Research Group healthcare managing director, Wendy Cheng for a discussion around developments in AI regulation for pharmaceuticals, clinical trials, and drug development at a global scale.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What Are the Top Oncology Clinical Trial Trends Through the Lens of ESMO?

XTalks

Estimates based on publicly available information suggest more than 40 percent of all new therapies in development are cancer treatments. Given this hotbed of activity, innovation in the space to drive faster decisions and more efficient trials is intense.

article thumbnail

Rivus raises $132m to advance clinical development of obesity treatment

Pharmaceutical Technology

The CMAs of the company can lower fat throughout the body through mitochondrial uncoupling, a natural process that causes energy regulation. In the trial, HU6 treatment also led to a substantial decline in liver, visceral and total body fat while preserving skeletal muscle mass.

article thumbnail

Patient groups issue call to action on patient-centric clinical trials

Drug Discovery World

A new whitepaper has introduced the concept of ‘cross-over’ options in cancer clinical trials, as a way to make trials more patient-centric in design. It also encourages sponsors, investigators and regulators to advance patient-centric trial designs.

article thumbnail

IQVIA’s report card for clinical trial diversity: must do better

pharmaphorum

The lack of diversity in clinical trials has been a topic of debate for decades, but was thrust into the spotlight as the impact of the pandemic on poorer, less educated and ethnically diverse populations became even more apparent. Both groups were poorly represented however in oncology trials. for Hispanics.

article thumbnail

Diversity, Equity, and Inclusion Data Service for clinical development 

Drug Discovery World

The new service harnesses data from Phesi, and uses Krystelis’ writing services to empower sponsors to improve diversity from the trial planning stage onwards. It’s great to see companies like Phesi and Krystelis delivering practical solutions and services to help companies meet these new regulations quickly and effectively.